Edgestream Partners L.P. lowered its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 46.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 684 shares of the medical instruments supplier’s stock after selling 584 shares during the period. Edgestream Partners L.P.’s holdings in C.R. Bard were worth $219,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in C.R. Bard by 70.4% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 190 shares during the period. Parallel Advisors LLC raised its holdings in shares of C.R. Bard by 2.8% in the second quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock worth $164,000 after buying an additional 14 shares during the last quarter. Captrust Financial Advisors purchased a new position in shares of C.R. Bard in the second quarter worth $192,000. Choate Investment Advisors purchased a new position in shares of C.R. Bard in the second quarter worth $201,000. Finally, Stock Yards Bank & Trust Co. purchased a new position in shares of C.R. Bard in the second quarter worth $207,000. 79.27% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/edgestream-partners-l-p-has-219000-position-in-c-r-bard-inc-bcr/1675724.html.

C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.06. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The business had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. During the same quarter last year, the company earned $2.64 earnings per share. The business’s quarterly revenue was up 5.1% compared to the same quarter last year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. C.R. Bard’s payout ratio is currently 13.70%.

In other C.R. Bard news, insider Timothy P. Collins sold 55,818 shares of C.R. Bard stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $322.03, for a total value of $17,975,070.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Timothy P. Collins sold 8,388 shares of C.R. Bard stock in a transaction on Monday, October 9th. The stock was sold at an average price of $322.00, for a total transaction of $2,700,936.00. The disclosure for this sale can be found here. Insiders have sold 136,568 shares of company stock valued at $43,932,079 in the last three months. Corporate insiders own 0.80% of the company’s stock.

A number of research firms have recently issued reports on BCR. Needham & Company LLC reissued a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. Jefferies Group LLC restated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Thursday, September 14th. BidaskClub downgraded shares of C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets restated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a strong buy rating to the company. C.R. Bard has an average rating of “Hold” and a consensus target price of $292.00.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.